Conzeb is a Hong Kong biotechnology company focused on developing cancer diagnostic tools and big-data single-cell imaging assays using revolutionary ultra-fast optical imaging technologies. Previously a spin-off company at the University of Hong Kong, Conzeb is now part of Avalon’s platform and has the same goal of improving the quality of life and increasing the lifespan of people around the world. Down to 1-10 circulating tumour cells (CTCs) in billions of blood cells, current technologies are facing significant challenges in early cancer detection, generating false positive rates of up to 99.5% and introducing huge expenses on unnecessary diagnoses. Our ultra-fast optical imaging technologies have been designed to offer up to 100,000 cell images per second, which could potentially detect the tiny amount of rare CTCs in patient blood. Together with the new biophysical markers retrieved from over millions of cell images from patients, our cancer diagnosis solution is ultra-fast, blood-based and label-free. Our ultrafast imaging analytics also minimizes tedious sample pre-treatments and provides a quick and cost-effective diagnosis of CTCs or monitoring of disease status. We believe our novel and advanced concepts of optimal imaging will be able to extend and revolutionize healthcare applications, e.g. treatment monitoring and drug discovery processes, and generate tremendous benefits for the general public.